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Summaiy: Recently developed enzyme tests that are used in (a) identifying high risk populations, (b) diagnosing
cancer, (c) following treatment response of cancer patients, and (d) the selection of cancer therapy are summarized.
The diagnostic role of methionine adenosyltransferase and CSF monoamine oxidase activity measurements in the
diagnosis of schizophrenia are discussed. The role of N-acetyltransferase in the conversion of serotonin to melatonin
in the pineal gland and the importance of these changes for the synchronization of the functioning of cells through-
out the organism are described. New developments in the determination of immun ore active tiypsin in the early diag-
nosis of pancreatic diseases are summarized.
Gegenwärtige und zukünftige Trends in ausgewählten Gebieten der klinischen Enzymologie
Zusammenfassung: Kürzlich entwickelte Enzym-Tests für (a) die Identifizierung von Risiko-Populationen, (b) die
Diagnose von Carcinomen, (c) die Überprüfung des Therapieerfolgs bei Carcinom-Patienten und (d) die Wahl der Car-
cinomtherapie werden zusammenfassend besprochen. Die diagnostische Bedeutung der Bestimmung der Methionin-
Adenosyltransferase und der Monoaminoxidase im Liquor für die Diagnose der Schizophrenie wird diskutiert. Die
Rolle von N-Acetyltransferase im Stoffwechsel von Serotonin zu Melatonin in der Zirbeldrüse und dessen Bedeutung
für die Synchronisation der Zellfunktion über den gesamten Organismus werden beschrieben. Neue Entwicklungen
in der Bestimmung des immunreaktiven Trypsins zur Frühdiagnose von Pankreaserkrankungen werden zusammengefaßt.
Introduction
Some years ago, Albert Einstein stated, "Our time is dis-
tinguished by wonderful achievements in the field of
scientific understanding and the applications of these
insights."
This statement in its full import could be applied to
the field of clinical enzymology, since there are few areas
where developments have been so rapid, where the con-
tributions to the understanding of the human organism
have been so great, and where the benefits of scientific
achievement to mankind have been as pronounced.
If we take a look at one of the charts depicting the path-
ways of intennediary metabolism of human cells, we can
only be overwhelmed by the thousands of chemical reac-
tions tMt are known today. Most of these reactions are
catalyzed by enzymes, and over a thousand of these en-
zymes have so far been identified. There is evidence to
believe, however, that many more enzymes remain to be
) Keynote address given during the academic memorial services
for Professor Dr. Gabor Szdsz held in conjunction with the
Gabor Szasz Symposium, Trends in Clinical Enzymology,
November 9 and 10,1979, Giessen, Germany.
discovered and that enzymes hold the key to the under-
standing of many normal body functions as well as pa-
thological changes.
The Role of Enzymes in Cancer
The use of enzyme measurements in cancer goes back
many years, but must still be viewed as an application
that is just beginning to unfold. Enzymes have proven to
be potentially useful as tumor markers in the early de-
tection of cancer and metastases; in following progression
of disease and response to treatment; in the detection of
drug toxicity; arid in the selection of the proper treatment
of cancer if the diagnosis is once firmly established.
Much future effort must be expended to identify other
enzymes and isoenzymes with greater sensitivity and
specificity, with regard to pinpointing the site of a pri-
mary tumor or metastases. The search will extend from
serum to other body fluids, such as urine, effusions, cysts
and spinal fluid, as well as tissues and tissue scrapings.
Efforts will be intensified to define high-risk populations
and to improve our ability to determine treatment agents
that are most likely to be of highest effectiveness. The
search for suitable enzyme profiles and proper combina-
tions of these with tests for tumor-associated antigens or
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other chemical tests will increase and strengthen our diag-
nostic and prognostic capabilities. Last, but not least, the
study of enzymes will continue to be part of an overall
investigation into the understanding of the malignant
process as a whole.
A small selection of the most important, recent applica-
tions of enzyme tests are given below. Well established
tests are not considered even though they may still have
significant clinical usefulness.
Acid phosphatase in serum has been used in the detec-
tion of prostatic carcinoma for about 40 years. Unfortun-
ately traditional spectrophotometric tests for the mea-
surement of acid phosphatase detect about 90% of cases
of prostatic cancer only after metastasis has taken place
(1). However, recently developed immunochemical and
radioimmunochemical techniques are said to be more
sensitive and possibly more specific than former tech-
niques.
The detection rates for prostatic cancer of Stages I, II, III,
and IV, using the spectrophotometric enzyme methods
were found to be 12,15, 29, and 62% (2), making these
methods unsuitable for screening purposes. In contrast
to this, Foti (2,3) reported for the radioimmuno tech-
nique, a detection rate of 33, 79,71, and 92%. Unfor-
tunately, other studies have not shown such favorable re-
sults. New England Nuclear Laboratories give a detection
rate of 8, 21,40, and 86%, respectively, for their recent-
ly released product (4). Fleisher, in a personal communi-
cation, indicated a combined detection rate for Stage I
and Stage II cancer of approximately 40%. Differences
in technique and production of antibodies as well as dif-
ferences in the selection of the cut-off point are probable
causes for these discrepancies.
There is a certain overlap of results obtained on patients
with carcinoma of the prostate of Stages I and II on the
one hand, and normals and patients with diseases other
than prostatic cancer on the other hand. Above normal
values were obtained in some patients with benign pro-
static hypertrophy and in patients with other miscella-
neous conditions. The exact percentage depends on the
precise technique used and on the selection of the cut-
off point (1,2, 5).
Most of the reported results have been observed on hos-
pitalized populations suspected of having prostatic cancer,
i.e. a population with a high prevalence for this cancer.
If, however, the test is applied to a general population,
the predictive value of this test is still relatively low (6).
Aside from the low prevalence, this is due to the still re-
latively high rate of false positive results, i.e. the relati-
vely low specificity of the test. Thus, it appears presently
still doubtful that this technique is suitable as a screen-
ing procedure for the general population.
Efforts will undoubtedly continue to further refine this
technique, to improve the standardization of the assay,
and to compare this technique with counter-immunoelec-
trophoresis which is said to give fewer false positive re-
sults (5, 7). Similar efforts to detect other organ specific
enzymes by highly sensitive and specific techniques such
as RIA and counter^immunoelectrophoresis can be ex-
pected. Suggestions that this be explored for breast and
pancreatic cancer have already been advanced (8).
increases in ribonuclease activity in serum were observed
in a small number of patients with a variety of carcino-
mas, but mostly in pancreatic carcinoma. In one study,
28 of 30 patients had values two to seven times higher
than the normal control group (9).
Sialyltransferase appears to be a very sensitive indicator
for various forms of cancer, but especially of the colon
and breast (10). In one study of 134 randomly selected
patients with primary or metastatic cancer, 293 of 340
values were elevated (11). In a second study of 500 pa-
tients, abnormal activity was found in 80% of cases. This
compared with only 43% of elevated values for carcino-
embryonic antigen (12). Sialyltransferase is also a useful
indicator of treatment response. In 46 of 57 patients, the
enzyme activity correlated well with the clinical course
of the patients (11).
Galactosyltransferase isoenzyme //in serum has recent-
ly been claimed to be a sensitive marker for adenomas
of various organs. Activity of this isoen^me was in^
creased between 44 and 100% of the cases, depending
on the type of cancer (13) as shown in table 1.
In normal individuals, as well as in patients with non-
malignant disorders, no elevations of the isoenzyme II
were found, except in alcoholic hepatitis and in celiac
disease (13) (see tab. 2).
The degree of increase in enzyme activity correlates well
with the progression of the disease (fig. 1). Sera from pa-
tients with colonic cancer, falling in Duke's classification
A, had no significant elevations, while those in classifica-
tions B and C showed increasing levels of galactosyltrans-
ferase isoenzyme II. Highest levels were observed in pa-
Tab. 1. Galactosyltransferase II in malignant disorders (After
Podolsky, (13), reprinted by permission).
Name
Colorectal Adenocaicinoma
Pancreatic Adenocaicinoma
Gastric Adenocarcinoma
Esophageal Squamous-Cell Carcinoma
Breast Adenocarcinoma
Bronchogenic Carcinoma
Unknown Primary Source
Gallbladder and Bile-Duct Carcinoma
Prostatic Carcinoma
Lymphoma (Hodgkin type)
Chronic Lymphocytic Leukemia
Melanoma
Osteosarcoma
Hepatoma
Renal Carcinoma
All Cancers
Sera
tested
117
18
16
9
23
20
4
4
4
8
2
2
1
2
. 2
232
%
Positive
72.7
83.3
75.0
44.4
78.3
65.0
75.0
50.0
100*0
50:0
100,0
0
0
100.0
50.0
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Tab. 2. Galactosyltransferase II in non-malignant disorders
(After Podolsky, (13;, reprinted by permission;.
Name
Ulcerative Colitis
CVo/z/TsIleocolitis
Pancreatitis
Cholelithiasis
Biliary Cirrhosis
Alcoholic Hepatitis
Celiac Disease
Sera tested
12
8
15
4
2
15
20
% Positive
0
0
0
0
0
20.0
90.0
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Fig. 1. Correlation of serum galactosyltransferase isoenzyme II
levels with Duke's classification in colonic carcinoma
(13). Modified reprint, by permission from the New
England Journal of Medicine 299, 704 (1978;.
tients with distant metastases. Patients who had under-
gone successful colectomy no longer showed increases in
galactosyltransf erase isoenzyme II activity (13).
UDP galactose: glycoprotein galactosyltransferase activi-
ty was found to be 3 to 5 times higher in ovarian tumor
tissue than in normal tissue. Similar elevations were also
seen in the serum of patients with ovarian cancer (14).
Aryl-hydrocarbon hydroxylase is somewhat unique
inasmuch as it can be induced by polycyclic aromatic
hydrocarbons. These agents are hydroxylated by the en-
zyme to epoxides which then form covalent bonds with
nucleic acids and proteins. Individuals in whom high en-
zyme activity is induced by exposure to these hydrocar-
bons appear to be especially susceptible to bronchiogenic
carcinoma (15). Thus, this test is an example of the role
of enzymes in the detection of high risk populations
and the prevention of disease.
Recent work indicates that measurements ofglycolytic
enzymes (16) in breast tumor tissues are useful in the
diagnosis of breast tumors; but, most of all, they are help-
ful in deciding the best course of treatment if breast carci-
noma is once established. Here, it is more the enzyme pat-
tern than the abnormality of any given enzyme which is
of clinical usefulness.
Table 3 shows the activity of 6 glycolytic enzymes in
non-carcinomatous and carcinomatous breast tissue.
Phosphofructokinase, glucose-6-phosphate dehydrogenase,
6-phosphogluconate dehydrogenase, phosphoglucomu-
tase, lactate dehydrogenase and phosphohexose isomerase
all show significantly higher activities in cancer tissue as
compared to benign mammary dysplasia or normal breast
tissue (16).
These findings may have additional significance, since a
different study showed that cancer associated with high
levels ofglycolytic enzymes responds better to chemo-
therapy than cases associated with low enzyme activity
(17) (tab. 4).
Combining these findings with the experience obtained
with the presence of estrogen receptor proteins and res-
ponse to hormone therapy may give us a useful guide in
the selection of therapy for breast cancer.
Presence of estrogen receptor proteins and a low enzyme
profile suggest that hormone treatment will be most suc-
cessful. Presence of estrogen receptor proteins and a high
enzyme profile is an indication for hormone and chemo-
therapy. Absence of estrogen receptor proteins but pre-
sence of a high enzyme profile suggests chemotherapy.
If both estrogen receptor proteins and the enzyme pro-
file are low, no conclusions with regard to treatment can
be drawn from these results (17).
Tab. 3. Mean enzyme catalytic activity content of human breast tissue (U/mg tissue). From: Deshpande, N., et al. (16J.
Enzyme
Ph osphofructokinase
Glucbse-6-phosphate dehydrogenase
6-phosphogluconate dehydrogenase
Ph osphoglucomut se
Lactate dehydrogenase
Phosphohexose isomerase
Benign Mammary
Dysplasia
16
36
23
358
1068
1525
I
60*
133*
132*
1327*
6381*
7421
m&iv
119
226
144
1.383
8.963
10.903
Metastases
78
252
162**
1.802
8.478
10.233**
* Significant difference between Benign Mammary Dysplasia & Stage I Cancer
** Significant difference between Stage I & Metastases
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Tab. 4. Mean enzyme catalytic activity content of breast car-
cinomas of patients receiving chemotherapy (U/mg
DNA). From: #///,£., et al. (17).
Enzyme Re- Nonre-
sponders spenders
(17) (13)
Glucosephosphate isomerase
Lactate dehydrogenase
Isocitrate dehydrogenase
Pyruvate kinase
Glucose-6-phosphate dehydrogenase
6-phosphogluconate dehydrogenase
21.31
16.12
1.05
16.08
1.10
0.68
6.69
8.94
0.45
11.55
0.60
0.35
Tab. 5. Catechol-O-methyl transferase activity in human breast
tissue. From: Assicot.M., et al. (18).
Tissue
Normal Breast
Benign Tumor
Carcinoma
Grade I
Grade II
Grade III
(32)
(18)
(13)
(32)
(33)
Activity*
344 ± 83
570 ±155
555 ± 152
1538 ±328**
1716 ±450**
* Expressed as pmoles of radioactive metanephrine formed per
20 min per mg of cy tosol protein.
** Significant compared with normal breast.
crisis will have blast cells positive for terminal deoxy-
nucleotidyl transferase and will respond to an acute
lymphocytic leukemia-type therapy protocol. The re-
maining 70% will be negative for terminal deoxy-
nucleotidyl transferase and will be resistant to all
current forms of treatment (19).
Finally, I would like to point out two enzymes in spinal
fluid which are helpful in demonstrating metastatic
disease to the meninges. This is an especially important
application, since such metastases—if detected in the
early stage—respond to therapy in about 60% of cases
(20).
The first enzyme is ß-glucuronidase, which is present in
normal spinal fluid at nearly 30 mU/1. In meningeal
carcinomatosis, significant increases inactivity are
observed. On the other hand, only a few cases of menin-
geal lymphoma with brain parenchymal metastases and
with non-neoplastic mononuclear meningitis have values
above the normal range (20). The presence of meningeal
carcinomatosis can be further confirmed by measure-
ment of the lactate dehydrogenase isoenzyme-5 fraction,
which is increased to above 10% in this disorder. In
lymphomas or in leukemia, percentages of less than
10% are observed (20).
In general, tissue content of enzymes does not greatly
differ with the stage of illness. The enzyme catechol-O-
methyltransferase in breast tissue, however, is one of the
exceptions where we have a progression in increase in
values from normal breast tissue through Stages I, II,
and HI of cancer tissue (18) (tab. 5).
It is of particular interest that catechol-0-methyltrans-
ferase appears to be responsible for the 0-methylation
of catechol-estrogens and might affect estrogen action
on the tissues by acting as an anti-estrogen or inhibitor
of estrogen binding to receptor proteins. This aspect
should be the subject of further studies and could give
us valuable information regarding predicted response to
treatment.
Analysis of terminal deoxynucleotidyl transferase
activity in lymphocytes has proven to be most useful in
lymphoblastic disease for the confirmation of diagnosis,
determination of the appropriate treatment, and for
monitoring the response to treatment. The predicted
response for therapy in some malignant lymphomas and
leukemias is dependent on the cell phenotype; that is,
whether the tumor is composed of T, B or "null" cells
and whether or not the tissue is positive or negative for
terminal deoxynucleotidyl transferase. For example, in
childhood acute lymphocytic leukemia, the patient's
favorable response to therapy can be predicted by the
absence of T and B cell markers (i.e., presence of "null"
cells) and the presence of terminal deoxynucleotidyl
transferase activity. In chronic myelogeiious leukemia,
approximately 30% of those patients who enter "blast"
Schizophrenia
Another interesting development and area of predicted
future activity is the elaboration of the causes for
schizophrenia and the development of methods for the
diagnosis of this disorder. Schizophrenia affects millions
of individuals and its diagnosis is not only of interest for
initiation of proper treatment but may also be of ex-
treme importance for the determination of the guilt of
a defendant during a trial.
Defects in transmethylation have long been suspected as
a cause of schizophrenia, but it was not until recently
that deficiencies in serine hydroxymethyl transferase and
in the methionine-activating enzyme, methionine
adenosyltransferase, have been demonstrated in blood
(21). These deficiencies lead to a decrease in the produc^
tion of S-adenosylmethionine, the high energy methyl
donor.
Other, investigations (22) have suggested that the platelet
monoamine oxidase activity is reduced in chronic
schizophrenics (fig. 2) and that its measurement may
constitute a genetic marker for this disease.
Furthermore, there appears to be some evidence that
the enzyme, monoamine oxidase, exists in two iso-
enzyme forms: type A and type B (23). The type A
isoenzyme catalyzes predominantly the deamination of
norepinephrine and serotonin, while dppamine is
deaminated by both isoenzymes A and B (fig: 3).
Experimental data seem to show that chronic schizo-
phrenia appears to be related to a type B deficiency,
J. Clin. Chem. Clin. Biochem. / Vol. 18,1980 / No. 11
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Fig. 2. Frequency distribution for platelet monoamine oxidase
activity (substrate: benzylamine) in 332 female control
subjects (a; and 26 female chronic schizophrenic patients
(b) (22). Modified reprint, by permission from The
American Journal of Psychiatry 136, 381 (1979).
Dopomine
Monoamine oxidase A & θ
Η
Serotonin (5-hydrbxytryptamine)
Monoamine oxidase A
HO^ ^  * ^CH2-COOH
3.4-Dihydroxyphenylacetic acid
Catechol-0-rriethyltransferase
·„
5-Hydroxyindpleqcetic acid
Homovanillic Acid
Fig. 3. Pathway of serotonin and dopamine metabolism. After:
Tietz, Ϊ*. W., ed., Fundamentals of Clinical Chemistry,
W. B. Saunders, Philadelphia, 1976. Reproduced by
permission from the publisher.
which is accompanied by a decreased spinal fluid con-
centration of honiovanillic acid. On the other hand, low
values of-both 5-hydroxyindoleacetic acid and homo^
vanillic acid in bipolar depressed patients suggests a
deficiency of type A plus type B is enzymes (23).
Ift addition to the quantitative differences, studies of
the substrate specificity and the Michaelis-Menten con-
stant suggest that the isoenzyme B in schizophrenics is
different from that in normals.
While these findings do not show a causal relationship
between these enzyme deficiencies and the development
of schizophrenia, they seem to shed some light on a
disease which has fascinated and puzzled scientists for
many decades and indicate that further efforts could
give us greater insights into the cause of this disease.
Contradictory findings in the literature regarding enzyme
activities in schizophrenia, may at least in part, be due
to existing difficulties in classifying various forms of this
disease.
A Time-Keeping Enzyme in the Pineal Gland
Let us now turn away from the diagnostic'role of
enzymes and take a look at the involvement of these
catalysts in the mechanism of a biological clock—a
system which senses and communicates time and thus
regulates internal functions of an organism. Such a sys-
tem has, indeed, been partially elaborated in a variety of
vertebrate animals. These investigations have centered
around the role of serotonin and its conversion into the
hormone, melatonin.
Serotonin, in the presence of N-acetyltransferase, is
converted to N-acetyl-serotonin, which is then con-
verted to melatonin by the action of hydroxyindole-
O-methyltransferase. It has been found that the activity
of the melatonin synthesizing enzyme, hydroxyindole-O-
inethyltransferase, shows increases in activity during
the night of 20% in chickens and increases up to 300%
in some other animals (24).
This rhythm, however, is by far not as pronounced as
the recently discovered circadian rhythm of N-acetyl-
transferase, which shows peaks in the dark that are 27
to 70 times higher than the lowest value during the
period of light (fig. 4). This increase parallels closely
the production of melatonin (24). Through this mech-
anism, the pineal gland appears to function as a bio-
logical clock that is either controlled by or reset by
light.
Corresponding to this circadian rhythm of enzyme
activity, there is a change in serotonin and melatonin
levels. Experiments on rats, for example, have shown
that high levels of serotonin were found during the day
(or light time), while low serotonin levels were found
during the night (or dark time). Conversely, it was ob-
served that the level of pineal melatonin was low during
the day and high during the night. The low enzyme level
during the day apparently reduces the conversion of
serotonin to melatonin, while the high enzyme level
during the night increases this conversion (24).
It is entirely possible that the enzyme, N-acetyltrans-
ferase, by its periodic depletion of pineal stores of sero-
J. Clin. Chem. din. Biochem. / Vol. 18, 1980 / No. 11
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Fig. 4. Correlation of melatonin content and N-acetyltransferase
activity in the pineal gland during periods of light and
darkness. Modified from Binkley, S., et al., Pineal
Enzymes: Regulation of Avian Melatonin Synthesis.
Science 181, 273 (1973). Copyright 1973 by the Ameri-
can Association for the Advancement of Science. Re-
produced with permission.
tonin and production of melatonin from the gland, is
involved in synchronizing the functioning of the cells
throughout an entire organism. This hypothesis was
strengthened by the sleep-inducing and temperature-
lowering effect of melatonin, when injected into spar-
rows. Both of these effects are characteristic of the
nighttime physiology in these birds (24).
At this time we have no precise knowledge of the
mechanism by which the vertebrates sense the changes
from light to dark, and there is strong evidence'that the
system just described is not the only biological clock
of vertebrates.
Immunoreactive Trypsin
Pancreatitis is one of the first diseases in which an
enzyme test was used to support a clinical diagnosis.
Amylase was initially found to be elevated in the urine
and increases were subsequently confirmed in serum.
Despite the extensive experience with this and other
laboratory precedures, the diagnosis of pancreatitis
remains a difficult one.
Recent efforts of several investigators have lead to a
radioimmunochemical procedure which allows the
determination of trypsinogen and trypsin in serum in
the presence of its inhibitor, arantitrypsin. Preliminary
reports indicate that immunoreactive trypsin is a highly
sensitive and relatively specific indicator of pancreatic
disease.
In the first reported study (25), all 8 cases of pan-
creatitis showed elevations in immunoreactive trypsin,
varying from 150% to 4,000%. One pätfent with
parotitis with meningitis had normal immunoreactive
trypsin activity, in spite of a significant elevation in
plasma amylase.
In a second study (26), 2 patients with acute pancreati-
tis had 26 to 37 times the activity found in the control
group. Values in peritoneal fluid of two patients with
pancreatitis were 7 and 11 times the value of the control
serum pool.
In a third study (27), all 14 patients with acute pan-
creatitis showed 3 to 30-fold increases in immunoreac-
tive trypsin, compared with the control group. Immuno-
reactive trypsin levels in 11 of 16 patients with pan-
creatic cancer were also found to be abnormal, with 8
values being high and 3 values being low. In chronic pan-
creatitis, 15 of 23 patients showed abnormal values with
3 elevations and 12 values below the normal level
(fig. 5). The different values observed in chronic pan-
creatitis and carcinoma of the pancreas are probably
related to the amount of functioning pancreatic tissue
and/or to the degree of obstruction.
At this point, it is difficult to fully evaluate the con-
tribution which this test will make to the early .diagnosis
of pancreatic disease. This is partially due to the limited
experience with the test4 but also due to our inability to
accurately identify patients with pancreatitis. Even in-
vasive procedures cannot diagnose this disease with cer-
tainty. Early findings, however, seem to indicate that
this test may have a greater sensitivity than presently
available laboratory procedures, and its specificity also
seems to be superior to the widely used amylase and
lipase determinations in serum. The abnormal findings
in chronic pancreatitis (and especially in carcinoma of
the pancreas) may be a guide to the selection of further
procedures to identify an early pathological process in
the pancreas. In view of the fast growth rate and high
death rate of cancer of the pancreas, a sensitive marker
for the detection of early carcinoma is essential if treat-
ment is to be successful.
This radioimmunochemical procedure for trypsin is
just one of a number of similar tests which have found
J. Clin. Chem. Clin. Biochem. / VoL 18,1980 / No. 11
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Fig. 5. Serum-trypsin concentrations in various pancreatic and
other diseases. From: Elias, E. et al. Diagnostic importance
of changes in circulating concentrations of immunoreac-
tive trypsin. Lancet//, 67 (1977). Reproduced by permis-
sion from the publisher.
entry into the clinical laboratory. These tests are highly
sensitive, they are potentially more specific than present
procedures and they measure the actual amount of
enzymes present as opposed to the activity. Thus, it
can be expected that the.se procedures will be utilized
in our clinical laboratory to an increasing extent. I do
not anticipate, however, that radioimmunochemical
tests will fully replace spectrophotometric procedures
which are generally less expensive and offer greater
convenience. In certain instances, where we are more
interested in the enzyme activity than the amount of
enzyme, use of these techniques indeed would be in-
appropriate.
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